share_log

Morgan Stanley Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8

Morgan Stanley Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8

摩根士丹利對C4 Therapeutics保持同等權重,將目標股價上調至8美元
Moomoo 24/7 ·  02/26 10:42

Morgan Stanley analyst Terence Flynn maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target from $1 to $8.

摩根士丹利分析師特倫斯·弗林維持C4 Therapeutics(納斯達克股票代碼:CCCC)的權重相等,並將目標股價從1美元上調至8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論